drugset / Trial / NCT02226991

Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

NCT02226991

Phase 1 Completed 34 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to investigate the effects of steady-state Efavirenz (600 mg QD) on the steady-state pharmacokinetics of Tipranavir (500 mg BID) coadministered with Ritonavir (200 mg BID)

Timeline

Start
2006-04
Primary completion
2006-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified 600 mg
Subject Tipranavir Small molecule 500 mg
Background Ritonavir Other / unclassified 200 mg

Indications

No indication recorded.